Interpace Diagnostics Group’s (IDXG) Buy Rating Reaffirmed at Maxim Group

Interpace Diagnostics Group (NASDAQ:IDXG)‘s stock had its “buy” rating reaffirmed by analysts at Maxim Group in a report released on Wednesday, MarketBeat.com reports. They currently have a $3.00 price objective on the business services provider’s stock, down from their previous price objective of $5.00. Maxim Group’s target price indicates a potential upside of 209.28% from the company’s current price.

Separately, ValuEngine upgraded Interpace Diagnostics Group from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

Shares of Interpace Diagnostics Group (NASDAQ:IDXG) traded up $0.02 during mid-day trading on Wednesday, reaching $0.97. The company’s stock had a trading volume of 240,200 shares, compared to its average volume of 518,591. The company has a market capitalization of $25.39, a P/E ratio of 0.33 and a beta of 1.64. Interpace Diagnostics Group has a 1-year low of $0.72 and a 1-year high of $4.45.

Interpace Diagnostics Group (NASDAQ:IDXG) last issued its earnings results on Monday, November 13th. The business services provider reported ($0.15) earnings per share for the quarter. The business had revenue of $4.20 million during the quarter. Interpace Diagnostics Group had a negative return on equity of 5.69% and a negative net margin of 6.33%.

A hedge fund recently bought a new stake in Interpace Diagnostics Group stock. Virtu Financial LLC acquired a new stake in Interpace Diagnostics Group Inc (NASDAQ:IDXG) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 130,866 shares of the business services provider’s stock, valued at approximately $133,000. Virtu Financial LLC owned 0.49% of Interpace Diagnostics Group as of its most recent filing with the Securities & Exchange Commission. 5.74% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/14/interpace-diagnostics-group-idxg-given-a-3-00-price-target-by-maxim-group-analysts.html.

About Interpace Diagnostics Group

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply